Outlook Therapeutics, Inc.

DB:41O Stock Report

Market Cap: €51.7m

Outlook Therapeutics Management

Management criteria checks 3/4

Outlook Therapeutics' CEO is Larry Kenyon, appointed in Sep 2015, has a tenure of 9.42 years. total yearly compensation is $634.60K, comprised of 74.9% salary and 25.1% bonuses, including company stock and options. directly owns 0.019% of the company’s shares, worth €9.60K. The average tenure of the management team and the board of directors is 3 years and 6.5 years respectively.

Key information

Larry Kenyon

Chief executive officer

US$634.6k

Total compensation

CEO salary percentage74.9%
CEO tenure9.4yrs
CEO ownership0.02%
Management average tenure3yrs
Board average tenure6.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Larry Kenyon's remuneration changed compared to Outlook Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

-US$47m

Sep 30 2024US$635kUS$475k

-US$75m

Jun 30 2024n/an/a

-US$94m

Mar 31 2024n/an/a

-US$159m

Dec 31 2023n/an/a

-US$51m

Sep 30 2023n/an/a

-US$59m

Jun 30 2023n/an/a

-US$60m

Mar 31 2023n/an/a

-US$57m

Dec 31 2022n/an/a

-US$70m

Sep 30 2022n/an/a

-US$66m

Jun 30 2022n/an/a

-US$65m

Mar 31 2022n/an/a

-US$60m

Dec 31 2021n/an/a

-US$53m

Sep 30 2021US$3mUS$425k

-US$53m

Jun 30 2021n/an/a

-US$50m

Mar 31 2021n/an/a

-US$40m

Dec 31 2020n/an/a

-US$45m

Sep 30 2020US$1mUS$425k

-US$49m

Jun 30 2020n/an/a

-US$49m

Mar 31 2020n/an/a

-US$51m

Dec 31 2019n/an/a

-US$45m

Sep 30 2019US$2mUS$425k

-US$36m

Jun 30 2019n/an/a

-US$38m

Mar 31 2019n/an/a

-US$43m

Dec 31 2018n/an/a

-US$40m

Sep 30 2018US$716kUS$372k

-US$48m

Compensation vs Market: Larry's total compensation ($USD634.60K) is above average for companies of similar size in the German market ($USD467.33K).

Compensation vs Earnings: Larry's compensation has been consistent with company performance over the past year.

CEO

Larry Kenyon (58 yo)

9.4yrs

Tenure

US$634,597

Compensation

Mr. Lawrence A. Kenyon, also known as Larry, CPA, serves as Executive Vice President, Chief Financial Officer, Treasurer and Corporate Secretary of Outlook Therapeutics, Inc. since July 06, 2021. He serves...

Leadership Team

NamePositionTenureCompensationOwnership
Lawrence Kenyon
EVP, CFO9.4yrsUS$634.60k0.019%
€ 9.6k
Jeffrey Evanson
Chief Commercial Officer6.3yrsUS$768.03k0.12%
€ 60.2k
Joel Prieve
Senior Vice President of Licensing and M&A3yrsno datano data
Surendra Sharma
Senior Vice President of Medical Affairs2.1yrsno datano data
Jennifer Kissner
Senior Vice President of Clinical Development & Regulatory Affairsno datano datano data
Jedd Comiskey
Senior VP - Head of Europe1.3yrsno datano data

3.0yrs

Average Tenure

Experienced Management: 41O's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Lawrence Kenyon
EVP, CFO6.5yrsUS$634.60k0.019%
€ 9.6k
Kurt Hilzinger
Independent Director9.2yrsUS$95.00k0.074%
€ 38.2k
Ralph Thurman
Lead Independent Director6.8yrsUS$242.50k0%
€ 0
Julia Haller
Independent Director2.5yrsUS$79.00k0%
€ 0
Julian Gangolli
Independent Non-Employee Director4.8yrsUS$112.50k0%
€ 0
Gerd Auffarth
Independent Non-Employee Director4.8yrsUS$79.00k0%
€ 0
Faisal Sukhtian
Independent Chairman of the Board7.4yrsUS$113.00k0.011%
€ 5.5k
Yezan Haddadin
Independent Director7.3yrsUS$110.00k0.0099%
€ 5.1k
Andong Huang
Independent Director4.7yrsUS$75.00k0%
€ 0

6.5yrs

Average Tenure

59yo

Average Age

Experienced Board: 41O's board of directors are considered experienced (6.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/20 17:34
End of Day Share Price 2025/02/20 00:00
Earnings2024/12/31
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Outlook Therapeutics, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Brian Kemp DolliverBrookline Capital Markets
Kumaraguru RajaBrookline Capital Markets